Brief: Molecular Templates, Inc. Provides Update On MT-5111 Phase 1 Study

Molecular Templates

21/12/2020 23:23

Molecular Templates Inc  MTEM.O :
    * MOLECULAR TEMPLATES, INC. PROVIDES UPDATE ON MT-5111 PHASE
1
STUDY
    * MOLECULAR TEMPLATES INC - PHASE 1 STUDY DOSE ESCALATION
ONGOING
IN ALL HER2 POSITIVE TUMOR TYPES
    * MOLECULAR TEMPLATES INC - HER2 POSITIVE BREAST CANCER
EXPANSION
COHORT PLANNED TO BE INITIATED IN 1H21
    * MOLECULAR TEMPLATES INC - EXPANSION COHORTS IN ADDITIONAL
TUMORS
TYPES TO BEGIN WHEN MTD OR RECOMMENDED PHASE 2 DOSE IS REACHED
    * MOLECULAR TEMPLATES INC - MT5111 APPEARS TO BE WELL
TOLERATED
WITH NO DOSE LIMITING TOXICITIES (DLTS) OBSERVED IN ANY COHORT
    * MOLECULAR TEMPLATES INC - EXPECT TO PROVIDE AN UPDATE ON
RESULTS
FROM SUBJECT CURRENTLY ON TREATMENT IN 1H21
    * MOLECULAR TEMPLATES INC -  EXPECT TO PROVIDE AN UPDATE ON
RESULTS FROM HIGHER DOSE COHORTS FROM DOSE ESCALATION PORTION OF
PHASE 1 STUDY IN 1H21

Source text for Eikon:  ID:nGNX1TccXK 
Further company coverage:  MTEM.O